ReviewAmerican journal of translational research2025
Effects of montelukast on allergic rhinitis in children: a systematic review and meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the efficacy and safety of montelukast in the treatment of allergic rhinitis (AR) in children through a meta-analysis.
methodsPubmed, Embase, and Cochrane Library were retrieved for randomized controlled trials and cohort studies on montelukast for pediatric AR from databases inception to June 2025. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias. Meta-analysis was conducted using RevMan5.3. Effect size was expressed as weighted mean difference (WMD) or odds ratio (OR) with 95% confidence interval (CI).
resultA total of 14 studies were included. Those treated with non-montelukast regimens were set as Group A, and those treated with montelukast were set as Group B. Meta-analysis showed that the total effective rate in group B was significantly higher than that in group A [
conclusionMontelukast improves the total effective rate and clinical symptoms of pediatric AR with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.